Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Beam Therapeutics Inc (NQ: BEAM ) 23.50 +0.09 (+0.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Beam Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins April 12, 2024 Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO: Via Benzinga Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol April 02, 2024 Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with... Via Benzinga Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts March 27, 2024 Via Benzinga Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) March 26, 2024 Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024 From Beam Therapeutics Via GlobeNewswire Navigating 4 Analyst Ratings For Beam Therapeutics February 28, 2024 Via Benzinga Recap: Beam Therapeutics Q4 Earnings February 27, 2024 Via Benzinga MarketBeat Week in Review – 3/4 – 3/8 March 09, 2024 The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hot Via MarketBeat Topics Artificial Intelligence Economy Exposures Artificial Intelligence Interest Rates Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments March 06, 2024 Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place Via MarketBeat Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences February 28, 2024 From Beam Therapeutics Via GlobeNewswire Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat February 27, 2024 Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. Via Investor's Business Daily Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug February 27, 2024 Both companies are working on treatments for genetic disorders. Via Investor's Business Daily Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session February 27, 2024 Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. Via Benzinga Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday February 27, 2024 U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage Gain February 27, 2024 Via Investor Brand Network Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones February 27, 2024 From Beam Therapeutics Via GlobeNewswire Is CRISPR Therapeutics the NVIDIA of gene editing? February 26, 2024 CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Product Safety Beam Therapeutics Stock Shows Healthy Relative Strength Improvement February 16, 2024 In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. Via Investor's Business Daily Analysts see over 50% gains in these 2 mid-cap biotech stocks February 14, 2024 The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence COVID-19 Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss February 08, 2024 Via Benzinga 3 Biotech Stocks to Buy on the Dip: February 2024 February 07, 2024 Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities Via InvestorPlace Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 05, 2024 From Beam Therapeutics Via GlobeNewswire Why Beam Therapeutics Stock Zoomed 17% Higher Today January 29, 2024 JPMorgan Chase becomes the latest institution in the company's bull pen. Via The Motley Fool 2 gene editing stocks to keep on your 2024 watchlist January 23, 2024 Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Via MarketBeat Exposures Product Safety Bitcoin, Ethereum, Dogecoin Rise As Investors Weigh Spot ETF Impact: Analyst Says Scenario For King Crypto Is 'Rejection' At $46K And Then Correction To Below $40K January 16, 2024 Major cryptocurrencies on Tuesday evening posted some gains following a weekend characterized by Via Benzinga Topics ETFs Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market January 16, 2024 Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry. Via InvestorPlace Exposures Product Safety 3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street January 16, 2024 Analysts have high hopes for these three innovation companies in 2024. Via The Motley Fool 3 Stocks to Buy in the Booming Field of Gene Editing January 11, 2024 As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. Via InvestorPlace Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones January 08, 2024 From Beam Therapeutics Via GlobeNewswire 4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 January 08, 2024 Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run. Via The Motley Fool Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.